1. Scrip
  2. >>New Products

Boehringer’s Spesolimab Wins First Approval In Rare Skin Condition

May Commercialize Therapy Alone

 
• By Ayisha Sharma

The German firm’s monoclonal antibody has received a US thumbs-up for a severe skin disease with high unmet need but it must address diagnostic and educational hurdles.    

Start track. Lanes 1, number one of a red racing track.
The US Nod Marks Boehringer's First Major New Drug Approval In Years • Source: Shutterstock

Boehringer Ingelheim GmbH’s spesolimab is the first drug approved for generalized pustular psoriasis (GPP) flares but the niche indication could present challenges surrounding diagnosis and awareness.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip